Plasma Adrenomedullin and Obstructive Sleep Apnea

8Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances. Methods: Plasma ADM levels were measured at 9:30 PM, 2:00 AM (after 4 to 5 h of untreated OSA), and 6:00 AM (after 4 h of continuous positive airway pressure treatment) in 15 OSA patients and in 10 controls. Results: Baseline ADM levels were similar in the OSA and control groups (28.7 ± 6.7 v 27.7 ± 6.4 pg/mL, respectively), did not change overnight in either group, and were not affected by continuous positive airway pressure. Conclusions: OSA does not exert any significant acute or chronic effects on plasma ADM levels. © 2004 American Journal of Hypertension, Ltd.

Cite

CITATION STYLE

APA

Wolk, R., Svatikova, A., Otto, M. E., Hoffmann, M. S., Duenwald, C. J., & Somers, V. K. (2004). Plasma Adrenomedullin and Obstructive Sleep Apnea. American Journal of Hypertension, 17(1), 74–76. https://doi.org/10.1016/j.amjhyper.2003.09.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free